Anti-iNOS antibody [RM1017] (Ab283655)
NOS2A, NOS2, Hepatocyte NOS, Inducible NO synthase, NOS type II, Peptidyl-cysteine S-nitrosylase NOS2, HEP-NOS, Inducible NOS, iNOS, Inosl, Nos2, Inducible NO synthase, Macrophage NOS, NOS type II, Peptidyl-cysteine S-nitrosylase NOS2, Inducible NOS, iNOS, MAC-NOS
详细信息
特异性
We have preliminary internal testing data to indicate this antibody may not be suitable for human ICC/IF and showed no staining in mouse and rat tissue samples by IHC-P. FURTHER INFORMATION ON SPECIFICITY (Chinese Version) available under the product protocols section. This file includes key technical notes of experience when using this product.
背景信息
Product Specifications Anti-iNOS antibody [RM1017] (ab283655) is a recombinant rabbit multiclonal antibody which is comprised of multiple monoclonal antibodies targeting different epitopes and recapitulating the performance of a polyclonal. Each component clone was developed by Abcam using patented rabbit monoclonal antibody technology. Anti-iNOS antibody [RM1017] (ab283655) is validated for use in Flow Cyt (Intra), I-ELISA, ICC/IF, IHC-P, IP and WB in human, mouse and rat samples. Anti-iNOS antibody [RM1017] (ab283655) specifically detects iNOS (UniProt ID: P35228; Molecular weight: 131kDa) and is sold in a convenient trial size to enable initial testing (20 µL) and larger sizes for subsequent scaling up experiments (100 µL and 1 mL). Quality and Validation Abcams high quality manufacturing and validation processes ensure Anti-iNOS antibody [RM1017] (ab283655) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. Related Products Conjugation-ready, carrier free format available for antibody clone RM1017 - ab283668. What are recombinant multiclonals? Recombinant multiclonals are a mixture of recombinant antibodies co-expressed from a library of heavy and light chains. They offer several advantages including - The sensitivity of polyclonal antibodies by recognising multiple epitopes - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production View our range of recombinant multiclonal antibodies. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents.
文献引用 (129)
A dual-functional engineered exosome-laden hydrogel redirects endogenous neural stem cell fate for spinal cord injury repair.
一种双功能工程化外泌体负载水凝胶可改变内源性神经干细胞的命运，用于脊髓损伤修复。
Spatiotemporally engineered microneedle for microenvironment remodeling propels mucosal regeneration after tracheal mucosal injury.
时空工程化的微针可重塑微环境，促进气管黏膜损伤后的黏膜再生。
Synovial inflammatory macrophage-derived extracellular vesicles exacerbate cartilage lesions with a FMRP-selectively sorted manner in osteoarthritis
在骨关节炎中，滑膜炎症巨噬细胞来源的细胞外囊泡以FMRP选择性分选的方式加剧软骨损伤
Longitudinal in vivo (R)-[(18)F]FBFP PET imaging for preclinical evaluation of cerebral sigma-1 receptor after ischemic stroke.
纵向体内 (R)-[(18)F]FBFP PET 成像用于缺血性中风后脑 sigma-1 受体的临床前评估。
Clusterzymes-driven therapy: ultrasmall Cu(4) nanoclusters achieve dual-pronged synergistic effects on antioxidant defense and ferroptosis Inhibition for inflammatory osteolysis.
簇酶驱动疗法：超小 Cu(4) 纳米簇对炎症性骨溶解的抗氧化防御和铁死亡抑制具有双重协同作用。
Bilayer gelatin-methacryloyl scaffold for pulp inflammation suppression and dentin-like tissue regeneration.
用于抑制牙髓炎症和促进牙本质样组织再生的双层明胶-甲基丙烯酰支架。
Mannose Oligosaccharide-Conjugated In Situ Pore-Forming Injectable Hydrogels for Rheumatoid Arthritis Treatment by Reprogramming Macrophage Extracellular Vesicles
通过重编程巨噬细胞外囊泡，制备用于治疗类风湿性关节炎的甘露糖寡糖偶联原位成孔注射水凝胶
Immunomodulatory and dentinogenic potential of surface-engineered hesperetin-functionalized composite scaffolds for pulp-dentin regeneration.
表面工程化橙皮素功能化复合支架在牙髓牙本质再生中的免疫调节和牙本质生成潜力。
Mesenchymal stem cells-derived TGF-β1 promotes polarization of M2 macrophages in mice with acute-on-chronic liver failure via FOSL1/MERTK axis.
间充质干细胞衍生的 TGF-β1 通过 FOSL1/MERTK 轴促进急性加慢性肝衰竭小鼠体内 M2 巨噬细胞的极化。
Inhalation of mesenchymal stromal cell-derived extracellular vesicles activates macrophage polarization through the miR-22-3p/NLRP3/IL-1β pathway, ameliorating lung ischemia - reperfusion injury.
吸入间充质基质细胞衍生的细胞外囊泡可通过 miR-22-3p/NLRP3/IL-1β 通路激活巨噬细胞极化，从而改善肺缺血再灌注损伤。
- 1
- 2
- 3
- 4
- 5
- 6
- 13